The study will enroll up to 80 adults who are undergoing the surgical removal of two or more molar teeth for inflammatory and pain management.

February 16, 2024

US-based biopharmaceutical company Halia Therapeutics has begun a Phase II clinical trial to assess the efficacy of its drug candidate HT-6184 in managing post-procedural inflammatory and pain responses.

The company dosed the first subject undergoing wisdom tooth extraction with HT-6184.

The placebo-controlled, double-blind trial aims to evaluate the potential of HT-6184 to reduce diagnostic biomarkers of acute inflammation and pain following the procedure after the third molar extraction.

It will enroll up to 80 adults who are undergoing the surgical removal of two or more molars, with a minimum of one being partially or fully impacted in the mandibular bone.

Participants will receive a single oral dose of HT-6184 or a placebo before their oral surgery. They will subsequently be monitored for pain intensity and biomarkers of acute inflammation through five blood draws.

This is in addition to two follow-up appointments on the first and second days following surgery, along with follow-up phone calls five to seven days post-operation.

https://www.clinicaltrialsarena.com/news/halia-trial-pain-management/